Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?

There are essentially no good data describing the safety and efficacy of immune checkpoint inhibitors in patients with compromised organ function. The issue is complex, in that altered liver function will change protein binding of the drugs, potentially alter catabolism etc. Autoimmune hepatitis has been reported to occur, though it is relatively infrequent. Having said that, one must also realize that there are relatively few options for patients with advanced non-small cell lung cancer. I beli...